Literature DB >> 12755935

Pleuro-pulmonary involvement in children with blunt splenic trauma.

A Gorenstein1, M Witzling, L T Haftel, A Mandelberg, F Serour.   

Abstract

OBJECTIVE: Evaluation of the importance of pleuro-pulmonary involvement in paediatric patients with blunt splenic trauma.
METHOD: A retrospective chart review of 27 patients, aged 2-16 years, treated for blunt splenic injury between 1992 and 1999 was performed.
RESULTS: All patients except one were treated conservatively. In 12 patients (44.4%) left-sided pleuro-pulmonary involvement was diagnosed as primary traumatic injury or as a late complication. While Grade I and II splenic injuries were prevalent, pleuro-pulmonary involvement patients had a more severe degree of splenic injury. Chest pain, dyspnoea and diminished respiratory sounds were present on primary examination in patients with chest trauma. Body temperature during the first 5 post-trauma days was significantly higher among pleuro-pulmonary involvement patients. Specific pleuro-pulmonary involvement diagnoses on admission in six children with primary chest trauma were: lung contusion, pleural thickness, or haemo-pneumothorax. Three of them developed delayed pleural effusion. In the other six children with pleuro-pulmonary involvement, late complications appeared during 2-5 days post-trauma.
CONCLUSIONS: Pleuro-pulmonary involvement was observed in almost half of patients with blunt splenic trauma. Pleuro-pulmonary involvement occurred either early as a result of direct chest trauma or was delayed. High suspicion, careful monitoring of body temperature and repeated chest X-ray studies are recommended for early diagnosis and treatment of delayed pleuro-pulmonary involvement.

Entities:  

Mesh:

Year:  2003        PMID: 12755935     DOI: 10.1046/j.1440-1754.2003.00130.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  1 in total

1.  Splenomegaly, anaemia and pleural effusion.

Authors:  P Kojodjojo; S Chew; K Wakeham; R Lancaster
Journal:  J R Soc Med       Date:  2005-01       Impact factor: 18.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.